(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 28.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.17%.
Celcuity's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast CELC's revenue for 2026 to be $1,169,108,021, with the lowest CELC revenue forecast at $312,934,620, and the highest CELC revenue forecast at $2,985,897,365. On average, 12 Wall Street analysts forecast CELC's revenue for 2027 to be $17,625,538,937, with the lowest CELC revenue forecast at $8,752,344,102, and the highest CELC revenue forecast at $34,726,408,840.
In 2028, CELC is forecast to generate $35,879,894,693 in revenue, with the lowest revenue forecast at $12,931,519,634 and the highest revenue forecast at $62,832,555,606.